JAK inhibitors vs biologics in RA: how to frame the risk conversation
Choosing JAK inhibitors vs biologics in RA? Weigh FDA boxed warnings, age, heart risk, smoking, cancer and clot history for clearer shared decisions in practice
Treatments and Therapies
B-cell depletion in lupus nephritis — who, when, and why
Know when CD20 B-cell depletion fits lupus nephritis: rituximab vs obinutuzumab, class III-V timing, 2024 ACR guidance, risks, and measurable response goals.